<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152409</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000525</org_study_id>
    <nct_id>NCT03152409</nct_id>
  </id_info>
  <brief_title>Salicylic Augmentation in Depression</brief_title>
  <acronym>SAD</acronym>
  <official_title>Salicylic Augmentation in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessica Harder, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are doing this research study to find out if using aspirin along with
      antidepressant treatment can lessen symptoms of depression. This study also aims to find out
      if some people improve more from taking aspirin than others. The investigators also want to
      see if it is possible to predict which participants will do better based on a blood test.

      Aspirin is approved by the U.S. Food and Drug Administration (FDA) as an over-the-counter
      pain medication. But, aspirin is not approved by the FDA to make antidepressant treatment
      better.

      This research study will compare aspirin to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-control trial. The primary aims of this
      study are:

      Aim 1: To evaluate the clinical effect of aspirin augmentation on depression.

      Aim 2: To assess the inflammatory profile of the blood of the aspirin augmentation responders
      compared with the non-responders.

      Aim 3: To evaluate whether immune gene expression patterns are associated with antidepressant
      response to aspirin.

      Aim 4: To collect samples for later, more detailed immunologic characterization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial with about half of all participants receiving placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study team will be blinded to participant condition. Pharmacy will be responsible for providing study drug versus identical placebo to participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Scale score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in HDRS score in the treatment versus control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of inflammatory biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>Response of inflammatory biomarkers in treatment responders versus treatment non-responders at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker association with antidepressant response</measure>
    <time_frame>2 years</time_frame>
    <description>Ability to observe the degree of biomarker association with antidepressant response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Aspirin augmentation to treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo augmentation to treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 325mg</intervention_name>
    <description>Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.</description>
    <arm_group_label>Aspirin augmentation to treatment</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>Bayer</other_name>
    <other_name>Salicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.</description>
    <arm_group_label>Placebo augmentation to treatment</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current diagnosis of major depressive disorder

          -  Hamilton Depression Rating Scale (HDRS) score of &gt;21

          -  Stable treatment regimen (no medication changes or changes in psychotherapy treatment
             in past 8 weeks, and no participation in stepped treatments, such as completion of a
             course of cognitive behavioral therapy, during the trial)

          -  Failed to remit with up to 2 sequential antidepressant trials, or combination of 1
             antidepressant and 1 augmentation agent

          -  Women of childbearing age must agree to use an approved method of contraception for
             the duration of the study

        Exclusion Criteria:

          -  Active suicidal ideation

          -  History of manic episodes or psychosis

          -  Alcohol or substance use disorder within the past 6 months

          -  Comorbid neurologic condition affecting the central nervous system

          -  Comorbid autoimmune condition

          -  History of thyroid disease or a current abnormal thyroid-stimulating hormone (TSH)

          -  Active or recent (within the past month) infection (such as otitis, pneumonia, urinary
             tract infection); temperature &gt; 100.3 or white blood cell (WBC) count &gt; 11 K/microL
             will be considered evidence of active infection even in the absence of other symptoms

          -  History of GI bleed

          -  History of stroke

          -  History of a bleeding disorder

          -  Platelet count &lt; 150,000/mm3 on initial screening

          -  On a blood-thinning agent or taking NSAIDs daily

          -  Current use of oral steroids or other immunomodulating medications

          -  Salicylate sensitivity

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Harder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Harder, MD</last_name>
    <phone>617-732-6753</phone>
    <email>jaharder@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Molly O'Reilly</last_name>
    <phone>617-525-8443</phone>
    <email>MOREILLY2@PARTNERS.ORG</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Harder, MD</last_name>
      <phone>617-732-6753</phone>
      <email>JAHARDER@PARTNERS.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Molly O'Reilly</last_name>
      <phone>617-525-8443</phone>
      <email>moreilly2@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Harder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Philip NS, Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010 Apr;11(5):709-22. doi: 10.1517/14656561003614781. Review.</citation>
    <PMID>20151847</PMID>
  </reference>
  <reference>
    <citation>Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O'Neil A, Davey CG, Sanna L, Maes M. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013 Mar 18;11:74. doi: 10.1186/1741-7015-11-74. Review.</citation>
    <PMID>23506529</PMID>
  </reference>
  <reference>
    <citation>Iyengar RL, Gandhi S, Aneja A, Thorpe K, Razzouk L, Greenberg J, Mosovich S, Farkouh ME. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med. 2013 Nov;126(11):1017.e11-8. doi: 10.1016/j.amjmed.2013.02.037. Epub 2013 Aug 29.</citation>
    <PMID>23993259</PMID>
  </reference>
  <reference>
    <citation>Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006 Jul;11(7):680-4. Epub 2006 Feb 21.</citation>
    <PMID>16491133</PMID>
  </reference>
  <reference>
    <citation>Eyre HA, Air T, Proctor S, Rositano S, Baune BT. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:11-6. doi: 10.1016/j.pnpbp.2014.10.003. Epub 2014 Oct 16. Review.</citation>
    <PMID>25455584</PMID>
  </reference>
  <reference>
    <citation>Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry. 2012 Oct;169(10):1065-72. doi: 10.1176/appi.ajp.2012.11091325.</citation>
    <PMID>23032386</PMID>
  </reference>
  <reference>
    <citation>Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607-11. doi: 10.1002/da.20589.</citation>
    <PMID>19496103</PMID>
  </reference>
  <reference>
    <citation>Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012 Dec 10;141(2-3):308-14. doi: 10.1016/j.jad.2012.03.033. Epub 2012 Apr 18.</citation>
    <PMID>22516310</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jessica Harder, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Treatment</keyword>
  <keyword>Salicylic acid</keyword>
  <keyword>anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

